Trial Profile
BoTN: Onabotulinumtoxin A for the treatment of trigeminal neuralgia: Efficacy, safety and neurophysiological alterations under therapy – a prospective, controlled trial BoTN: Onabotulinumtoxin A zur Behandlung der Trigeminusneuralgie: Wirksamkeit, Sicherheit und neurophysiologische Veränderungen unter Therapie - eine prospektive, kontrollierte klinische Studie
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2014
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Trigeminal neuralgia
- Focus Therapeutic Use
- Acronyms BoTN-Study
- Sponsors Allergan
- 07 Sep 2014 Planned End Date changed to 26 Aug 2016.
- 07 Sep 2014 New trial record